Skip to main content
. 2016 Jul 12;24(11):1913–1925. doi: 10.1038/mt.2016.114

Figure 4.

Figure 4

Antiviral potency of ImmTAV-redirected healthy donor CD8+ T-cells against HIV-infected CD4+ T-cells from patients. Purified primary CD4+ T-cells (1 × 105) from 8 HIV-positive HLA-A*0201-positive ART-treated subjects were stimulated with PHA to reactivate latent HIV, then cultured with CD8+ T-cells from an HIV-negative donor at (a) a CD8+/CD4+ cell ratio of 1:1, alone or with ImmTAVs at the concentrations indicated; (b) a CD8+/CD4+ ratio of 1:10, alone or with m121 and m134 − 10–11 mol/l, irrelevant TCR-anti-CD3 scFV fusion (control TCR) − 10–12 mol/l. The same subjects are represented in a and b by the symbols in the legend. Reduction in Gag+ cells was determined on day 7 of coculture. Horizontal lines indicate mean values. Note that inhibition in the presence of the control TCR was negligible even when used at the same concentration as the HIV ImmTAVs. (c) Healthy donor CD8+ T-cells were sorted into subsets according to expression of CCR7 and CD45RA and cultured with purified PHA-activated CD4+ T-cells from two ART-treated patients at a ratio of 1:2, in the presence or absence of ImmTAVs (all at 10–9 mol/l) for 7 days. TEM – effector memory, CCR7−/CD45RA−; TEMRA – terminally differentiated effector, CCR7-/CD45RA+; TCM – central memory, CCR7+/CD45RA-; naive, CCR7+/CD45RA+. Reduction in Gag+ cells was determined on day 7 of co-culture. ART, antiretroviral therapy; PHA, phytohemagglutinin; HLA, human histocompatibility leukocyte antigen; HIV, human immunodeficiency virus; ImmTAV, immune-mobilising monoclonal T-cell receptors against virus; TCR, T-cell receptor.